Research programme: triptans - Angelini PharmaceuticalsAlternative Names: Triptans new formulations - Angelini
Latest Information Update: 15 Jul 2016
At a glance
- Originator Angelini Pharmaceuticals
- Class Analgesics
- Mechanism of Action Serotonin 1 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Migraine
Most Recent Events
- 15 Jul 2016 Preclinical trials in Migraine in Italy (unspecified route)